Dr Lal PathLabs

November 6, 2020

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex
Bandra (E)
Mumbai – 400 051.

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

Subject: Intimation under Regulation 30(2) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Please take note that pursuant to the approval of its Board, PathLabs Unifiers Private Limited ("PUPL") (a wholly owned subsidiary) has signed binding term sheets on 6 November, 2020 for the acquisitions of the business of Bindish Diagnostic Laboratory LLP ("BDL"), in Jamnagar, Gujarat on a going concern basis, for a purchase consideration not exceeding INR 40 million and equity stake of 70% in ChanRe Diagnostic Services Private Limited ("CDSPL"), in Bengaluru, Karnataka, for a purchase consideration not exceeding INR 175 million. BDL and CDSPL are engaged in the business of providing pathological diagnostic services

The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 are provided in the **Annexure I & II** attached to this letter.

We request you to kindly take the same on record.

Thanking You,

Yours Faithfully,
For **Dr. Lal PathLabs Limited**

Rajat Kalra
Company Secretary & Legal Head

Encl.: As above

Annexure-I

Sr. No.	Particulars in respect of the Event	Details/ Information of the Event
1.	Name of the target entity, details in brief such as size, turnover etc.	Name: Bindish Diagnostic Laboratory LLP **Turnover:** FY 2017-18 – 1.73 Cr. FY 2018-19 – Rs. 1.9 Cr. FY 2019-20 – Rs. 3.2 Cr.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	No, the transactions are not related party transactions.
3.	Industry to which the entity being acquired belongs.	Healthcare/ Diagnostics
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	To strengthen the Company's presence in the state of Gujarat.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	No government approvals required
6.	Indicative time period for completion of the acquisition	Within 3 month
7.	Nature of consideration - whether cash consideration or share swap and details of the same	Cash consideration
8.	Cost of acquisition or the price at which the shares are acquired	Not exceeding INR 40 million
9.	Percentage of shareholding / control acquired and / or number of shares acquired;	Complete Control
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information	M/s. Bindish Diagnostic Laboratory LLP provides range of pathology and diagnostic tests/services through their diagnostic laboratory situated in Jamnagar in the state of Gujarat. **Turnover:** As mentioned in clause 1 above.

Dr. Lal PathLabs Limited

Annexure-II

Sr. No.	Particulars in respect of the Event	Details/ Information of the Event
1.	Name of the target entity, details in brief such as size, turnover etc.	**NAME:** ChanRe Diagnostic Services Private Limited (which will house the business of ChanRe Diagnostics Laboratory) **Turnover**: Combined Turnover of ChanRe Diagnostic Services Private Limited and ChanRe Diagnostic Laboratory: FY 2017-18 – Rs. 9.52 Cr. FY 2018-19 – Rs. 10.35 Cr. FY 2019-20 – Rs. 11.51 Cr.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	No, the transactions are not related party transactions.
3.	Industry to which the entity being acquired belongs.	Healthcare/ Diagnostics
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	To strengthen the Company's presence in the state of Karnataka
5.	Brief details of any governmental or regulatory approvals required for the acquisition	No government approvals required
6.	Indicative time period for completion of the acquisition	Within 3 month
7.	Nature of consideration - whether cash consideration or share swap and details of the same	Cash consideration
8.	Cost of acquisition or the price at which the shares are acquired	Not exceeding INR 175 million
9.	Percentage of shareholding / control acquired and / or number of shares acquired;	Acquisition of 70% stake in ChanRe Diagnostic Services Private Limited.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information	ChanRe Diagnostic Services Private Limited, incorporated on May 21, 2015, a Company engaged in providing diagnostic services in the state of Karnataka **Turnover:** As mentioned in clause 1 above.

Dr. Lal PathLabs Limited